Tier 2 — strong

Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study

Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E
NPJ aging and mechanisms of disease 2017 3; 17

Bibliography

PubMed
PMID 29184669
PubMed Central
PMC5701244
DOI
10.1038/s41514-017-0016-9
Funding
Elysium Health funded the trial; KGK conducted it. Elysium supplied the NR/pterostilbene and placebo products.
Competing interests
Several authors were Elysium employees and shareholders.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample120 adults aged 60–80 years
InterventionNR plus pterostilbene (Basis), standard and double dose, versus placebo
Duration8 weeks
EndpointsWhole-blood NAD+; adverse events

What the study showed, in plain terms

The combination increased whole-blood NAD+ in older adults, with no serious adverse events reported during the trial.

Key findings

NAD+ rose approximately 40% and 90% in the two active arms at week 4.

What this study can and cannot tell us

The intervention contains two ingredients. Biomarker changes and short follow-up do not establish clinical efficacy or lifetime safety. Read with the published author correction.

Related papers in the corpus

Tier 4
Erratum: Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2018
Tier 4
Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial
Holmes HE et al. · Frontiers in aging · 2026
Tier 2
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Dellinger RW et al. · Hepatology (Baltimore, Md.) · 2023
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals
Jensen JB et al. · JCI insight · 2022
Tier 2
Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Simic P et al. · BMC nephrology · 2020

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology